Cargando…

MON-198 Feminizing Regimen Requirements in Transgender Females Following Orchiectomy

Introduction: Transgender females (TF) may undergo orchiectomy as part of their treatment. However, there is no clear recommendation in hormonal transition between pre- and post-orchiectomy (1, 2). Methods: All TF with orchiectomy in the transgender registry at Boston Medical Center (BMC) were revie...

Descripción completa

Detalles Bibliográficos
Autores principales: Korpaisarn, Sira, Safer, Joshua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551173/
http://dx.doi.org/10.1210/js.2019-MON-198
_version_ 1783424351843909632
author Korpaisarn, Sira
Safer, Joshua
author_facet Korpaisarn, Sira
Safer, Joshua
author_sort Korpaisarn, Sira
collection PubMed
description Introduction: Transgender females (TF) may undergo orchiectomy as part of their treatment. However, there is no clear recommendation in hormonal transition between pre- and post-orchiectomy (1, 2). Methods: All TF with orchiectomy in the transgender registry at Boston Medical Center (BMC) were reviewed. Feminizing regimens prior to and after orchiectomy were evaluated. The type, form and dose of hormones along with serum estradiol, testosterone, FSH and LH were assessed. Results: 124 TF consented to be included in the transgender registry at BMC. 23 of 124 (18%) TF had orchiectomy. 10/23 TF had the hormonal regimen available pre-orchiectomy and 6 months or more post-orchiectomy. All 10 TF used oral 17-beta estradiol. 6 TF were prescribed less estradiol relative to their pre-orchiectomy regimen, 3 were prescribed the same estradiol dose and 1 was prescribed a higher estradiol dose. An average of adjusted post-orchiectomy estradiol doses was 78% (range 50%-150%) of pre-orchiectomy dose. Among 10 TF with an available hormone regimen pre-and post-orchiectomy, 5 (50%) had serum estradiol at goal (100-200 pg/mL) and FSH in a pre-menopausal cis-female range. Among these 5 TF, the average of the adjusted post-orchiectomy estradiol dose was 96% (range 50%-150%) of the pre-orchiectomy dose. Estradiol doses up to 6 months or more following orchiectomy were available in 17 TF. 15 used oral 17-beta estradiol (average dose of 3.1mg/day with the range of 1-8 mg), 1 used oral conjugated estradiol and 1 used 17-beta estradiol gel. 7/17 had estradiol level at goal (100-200 pg/mL) and FSH in the pre-menopausal female range. All 7 TF used oral 17-beta estradiol. An average of post-orchiectomy estradiol doses was 2.85 mg/day (range 1-5 mg). Conclusion: Most TF who underwent orchiectomy had a lower estradiol dose (approximately 75% of the pre-orchiectomy regimen). However, to achieve the estradiol level at goal and maintain FSH in the the pre-menopausal female range, trans women required estradiol doses closer to the pre-orchiectomy regimen. The dose range of oral 17-beta estradiol in post-orchiectomy TF is 1-5 mg, similar to recommendations for TF who have not undergone orchiectomy (2-6 mg) (1). References: (1) Hembree et al., J Clin Endocrinol Metab. 2017 Nov 1;102(11):3869–903. (2) Coleman et al., International Journal of Transgenderism. 2012;13:4, 165-232.
format Online
Article
Text
id pubmed-6551173
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-65511732019-06-13 MON-198 Feminizing Regimen Requirements in Transgender Females Following Orchiectomy Korpaisarn, Sira Safer, Joshua J Endocr Soc Reproductive Endocrinology Introduction: Transgender females (TF) may undergo orchiectomy as part of their treatment. However, there is no clear recommendation in hormonal transition between pre- and post-orchiectomy (1, 2). Methods: All TF with orchiectomy in the transgender registry at Boston Medical Center (BMC) were reviewed. Feminizing regimens prior to and after orchiectomy were evaluated. The type, form and dose of hormones along with serum estradiol, testosterone, FSH and LH were assessed. Results: 124 TF consented to be included in the transgender registry at BMC. 23 of 124 (18%) TF had orchiectomy. 10/23 TF had the hormonal regimen available pre-orchiectomy and 6 months or more post-orchiectomy. All 10 TF used oral 17-beta estradiol. 6 TF were prescribed less estradiol relative to their pre-orchiectomy regimen, 3 were prescribed the same estradiol dose and 1 was prescribed a higher estradiol dose. An average of adjusted post-orchiectomy estradiol doses was 78% (range 50%-150%) of pre-orchiectomy dose. Among 10 TF with an available hormone regimen pre-and post-orchiectomy, 5 (50%) had serum estradiol at goal (100-200 pg/mL) and FSH in a pre-menopausal cis-female range. Among these 5 TF, the average of the adjusted post-orchiectomy estradiol dose was 96% (range 50%-150%) of the pre-orchiectomy dose. Estradiol doses up to 6 months or more following orchiectomy were available in 17 TF. 15 used oral 17-beta estradiol (average dose of 3.1mg/day with the range of 1-8 mg), 1 used oral conjugated estradiol and 1 used 17-beta estradiol gel. 7/17 had estradiol level at goal (100-200 pg/mL) and FSH in the pre-menopausal female range. All 7 TF used oral 17-beta estradiol. An average of post-orchiectomy estradiol doses was 2.85 mg/day (range 1-5 mg). Conclusion: Most TF who underwent orchiectomy had a lower estradiol dose (approximately 75% of the pre-orchiectomy regimen). However, to achieve the estradiol level at goal and maintain FSH in the the pre-menopausal female range, trans women required estradiol doses closer to the pre-orchiectomy regimen. The dose range of oral 17-beta estradiol in post-orchiectomy TF is 1-5 mg, similar to recommendations for TF who have not undergone orchiectomy (2-6 mg) (1). References: (1) Hembree et al., J Clin Endocrinol Metab. 2017 Nov 1;102(11):3869–903. (2) Coleman et al., International Journal of Transgenderism. 2012;13:4, 165-232. Endocrine Society 2019-04-30 /pmc/articles/PMC6551173/ http://dx.doi.org/10.1210/js.2019-MON-198 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Reproductive Endocrinology
Korpaisarn, Sira
Safer, Joshua
MON-198 Feminizing Regimen Requirements in Transgender Females Following Orchiectomy
title MON-198 Feminizing Regimen Requirements in Transgender Females Following Orchiectomy
title_full MON-198 Feminizing Regimen Requirements in Transgender Females Following Orchiectomy
title_fullStr MON-198 Feminizing Regimen Requirements in Transgender Females Following Orchiectomy
title_full_unstemmed MON-198 Feminizing Regimen Requirements in Transgender Females Following Orchiectomy
title_short MON-198 Feminizing Regimen Requirements in Transgender Females Following Orchiectomy
title_sort mon-198 feminizing regimen requirements in transgender females following orchiectomy
topic Reproductive Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551173/
http://dx.doi.org/10.1210/js.2019-MON-198
work_keys_str_mv AT korpaisarnsira mon198feminizingregimenrequirementsintransgenderfemalesfollowingorchiectomy
AT saferjoshua mon198feminizingregimenrequirementsintransgenderfemalesfollowingorchiectomy